Je was op zoek naar: oxaliplatin (Maltees - Engels)

oxaliplatin
oxaliplatin

oxaliplatin fl-ewwel ġurnata
oxaliplatin on day 1

oxaliplatin Ġurnata, kull 3 ġimgħat
oxaliplatin on day 1, every 3 weeks

oxaliplatin fl-ewwel Ġurnata, kull
oxaliplatin on day 1, every 2 weeks

oxaliplatin fl- ewwel Ġurnata, kull ġimagħtejn
oxaliplatin on day 1, every 2 weeks leucovorin on days 1 and 2, every 2

oxaliplatin fl- ewwel Ġurnata capecitabine orali bid għal
oxaliplatin on day 1

flimkien ma’ kimoterapija bbażata fuq irinotecan jew oxaliplatin:
in combination with irinotecan- or oxaliplatin-based chemotherapy:

oxaliplatin Ġurnata, kull 3 ġimgħat capecitabine mill- ħalq darbtejn
oxaliplatin capecitabine

kimoterapija bbażata fuq fluoropyrimidine/irinotecan jew fluoropyrimidine/oxaliplatin
fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy

oxaliplatin fl- ewwel Ġurnata leucovorin fl- ewwel u fit- tieni
oxaliplatin on day 1

ikkombinat ma’ bevacizumab u kimoterapija bbażata fuq oxaliplatin jew irinotecan bħala trattament tal-ewwel għażla
first-line combination with bevacizumab and oxaliplatin or irinotecan-based chemotherapy

sorafenib ma kellu l- ebda effett fuq il- farmakokinetika ta ’ gemcitabine jew ta ’ oxaliplatin.
sorafenib had no effect on the pharmacokinetics of gemcitabine or oxaliplatin.

il-pazjenti kollha irċevew kura minn qabel b’kimoterapija bbażata fuq fluoropyrimidine, oxaliplatin, u irinotecan.
all patients received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

zaltrap ġie investigat fi studju prinċipali wieħed li kien jinvolvi 1,226 adult b'kanċer kolorettali metastatiku li ma kinux wieġbu għal kura bbażata fuq oxaliplatin.
zaltrap was investigated in one main study involving 1,226 adults with metastatic colorectal cancer that had not responded to oxaliplatin-based treatment.

capecitabine intuża wkoll f’taħlita ma’ oxaliplatin għall-kura ta’ kanċer avvanzat tal-istonku.
capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.

l-użu ta’ kors li fih irinotecan jew oxaliplatin kien maqlub skont l-użu ta’ oxaliplatin jew irinotecan bħala kura preferita.
use of irinotecan- or oxaliplatin-containing regimen was switched depending on first-line usage of either oxaliplatin or irinotecan.

l-oġġettiv maġġuri tal-istudju kien il-paragun ta’ pfs fil-ko-orti ta’ oxaliplatin.
the major study objective was comparison of pfs in the oxaliplatin cohort.

capecitabine intuża wkoll f’taħlita ma’ oxaliplatin għall-kura ta’ kanċer avvanzat ta’ l-istonku.
capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer.

eof: epirubicin (50 mg/ m2 bħala bolus fl- ewwel jum kull 3 ġimgħat), oxaliplatin (130 mg/ m2
- eof: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/ m2 given as

il-medjan tas-sopravvivenza globali kien ta’ 10.0 xhur f’korsijiet bbażati fuq cisplatin u 10.4 xhur f’korsijiet bbażati fuq oxaliplatin.
the median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin- based regimens.